[Federal Register: January 28, 2003 (Volume 68, Number 18)]
[Notices]
[Page 4233]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr28ja03-107]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on June 21, 2002, Bristol-Myers
Squibb Pharma Company, 1000 Stewart Avenue, Garden City, New York
11530, made application by renewal to the Drug Enforcement
Administration (DEA) for registration as a bulk manufacturer of the
basic classes of controlled substances listed below:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Oxycodone (9143)............................................ II
Hydrocodone (9193).......................................... II
Oxymorphone (9652).......................................... II
------------------------------------------------------------------------
The firm plans to manufacture the listed controlled substances to
make finished products.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substances may file comments or objections
to the issuance of the proposed registration.
Any such comments or objections may be addressed, in quintuplicate,
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, United States Department of Justice,
Washington, DC 20537, Attention: DEA Federal Register Representatives
(CCR), and must be filed no later than (60 days from publication).
Dated: January 6, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 03-1914 Filed 1-27-03; 8:45 am]
BILLING CODE 4410-09-M